Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Voyageur Pharmaceuticals Ltd VYYRF


Primary Symbol: V.VM

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > A Great New Add to the Executive Team
View:
Post by biggdogg on Sep 17, 2024 2:23pm

A Great New Add to the Executive Team

The criticism from those lacking education is often surprisingly quick. The Chief Science Officer's previous tenure at a pharmaceutical company, despite unsuccessful drug trials, should not be viewed negatively. It's all about the wealth of experience she brings. A brief internet search reveals much more and reveals that she is a remarkable hire. Sounds Like voyageur has the talent to advance with the FDA and their drug development, Impressive. This has been a position to be filled for a long time, it will bring credibility to the management team in the eyes of the pharma investment community.

Peer reviewed
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1317522/full
https://www.nature.com/articles/s42003-023-05536-0
https://www.frontiersin.org/journals/natural-products/articles/10.3389/fntpr.2023.1281061/full
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1119607/full
https://pubmed.ncbi.nlm.nih.gov/36923728/
https://www.nature.com/articles/s41598-021-91500-z
https://www.nature.com/articles/s41598-018-20608-6
https://www.nature.com/articles/srep30555
Patents
https://ipsearch.ipaustralia.gov.au/patents/2016228147
https://patents.google.com/patent/EP3265114A1/en
Comment by postie1 on Sep 17, 2024 4:03pm
There are probably many more failures than hits even by the best companies and scientists. I looked that up and if anybody thinks that a failure is a black mark on a persons' resume they had better think again. Clinical Trial Success Rates by Phase and Therapeutic Area | American Council on Science and Health (acsh.org)
Comment by biggdogg on Sep 17, 2024 4:25pm
13.8%, Thats an interesting success rate. 
Comment by WarrantOfficer on Sep 19, 2024 8:43am
Perhaps Dr Iryna Sarachova is the missing fullerene element to compliment the members of Voyageurs highly skilled Scientific Advisory Board: Deborah A. Baumgarten, MD, MPH Professor of Radiology, Mayo Clinic, Jacksonville, Fl. Fellow, Mayo Clinic, Academy of Academic Excellence Educational Liaison for Abdominal CT Rotation Interests: Gastrointestinal and Genitourinary ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities